Interview: António Portela, CEO, Bial Portugal
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Founded in 1924, BIAL is today the biggest Portuguese pharmaceutical group with a team of about 900 collaborators, and with a strong commitment to R&D, internationalization and quality.
BIAL is also an international pharmaceutical group with business activities in more than 50 countries. Based in Portugal, Bial owns facilities in Spain—where a production unit and a R&D centre dedicated to allergic immunotherapy are situated—Italy, Mozambique, Panama, and other countries.
Strongly committed to therapeutic innovation, investing more than 20 percent of its turnover in R&D every year, BIAL Group has launched the first drug of Portuguese patent, an anti-epileptic. Available since 2009 in several European markets, under the brand Zebinix, this antiepileptic, eslicarbazepine acetate, has recently been approved by the regulator of the pharmaceutical market in the US, Food and Drug Administration (FDA), for commercialization in the United States under the brand Aptiom.
BIAL has also a second pharmaceutical for its own research, for the treatment of the Parkinson disease, which is already in an advanced development process (phase III of clinical development).
The company expects to introduce more new medicines and vaccines to the market in the next years, specifically in the central nervous system, the cardiovascular system and allergen immunotherapy, which will be an added impetus to its international expansion.
Since 2005 the Bial Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA), which has recognized Bial as a research and development pharmaceutical company capable of bringing new medicines to the world to improve human health and the quality of life of the populations.
Bial Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award and Scientific Research Grants, well recognized worldwide.
Bial Contact Info:
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado – Portugal
Phone: +351 22986 6100 | Fax: +351 22986 6190
www.bial.com | info@bial.com
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
João Vasconcelos was the Secretary of State for Industry in Portugal over a two year period, terminating in July 2017, over which time he laid the foundations for Startup Portugal…
Pedro Moura is the first Portuguese managing director of Merck in Portugal, taking on the role in September 2017 after a stint in HQ in Darmstadt, Germany. Moura discusses Merck’s…
Enrique Santos, president of the Spanish Chamber of Commerce in Portugal since 1998, observes the rapid change in the volume and nature of investments into Portugal in recent years. Santos…
Azevedos is one of the oldest pharmaceutical brands in Portugal. Lead by Thebar Miranda, president for 30 years it operates across Portuguese speaking companies and distributes worldwide. In this interview,…
Florian Ibe, managing director at Bayer Portugal, discusses market access hurdles, as well as Portugal’s expertise in scientific and clinical research and highly educated workforce. In three years of his…
Paulo Lilaia, president of the board of APOGEN and CEO of Generis, highlights the need for generics in the healthcare system and the government’s approach to their implementation. He also…
The Portuguese secretary of state for industry invites readers to discover the vibrant tech landscape in Portugal. Ana Teresa Lehmann unravels the reasons why Portugal is such an exciting investment…
Filipa Costa returned to Portugal in September 2016 to take on the leadership of the fastest growing multinational affiliate in the country – Janssen. In this interview, she reveals her…
Heitor Costa, Executive Director for APIFARMA, the Portuguese Pharmaceutical Industry Association, outlines the recent improvements in industry and governmental agreements, the importance of non-prescription medicines, and raising societal awareness on…
A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017.…
Graca Didier, secretary general of AmCham Portugal, discuss the role of her chamber of commerce in promoting strong relations between America and Portugal. In addition, she comments on the cultural…
Joaquim Cunha, executive director of Health Cluster Portugal – a private, non-profit organisation dedicated to the consolidation of Portugal’s healthcare industry – discusses the up and coming changes to the…
See our Cookie Privacy Policy Here
